| Identification | Back Directory | [Name]
BCI-137
(BCI137) | [CAS]
112170-24-8 | [Synonyms]
BCI-137
(BCI137)
2-(2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonamido)propanoic acid | [Molecular Formula]
C11H11N3O6S | [MDL Number]
MFCD05148320 | [MOL File]
112170-24-8.mol | [Molecular Weight]
313.29 |
| Chemical Properties | Back Directory | [density ]
1.566±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 100mg/mL | [form ]
Solid | [pka]
3.30±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
BCI-137 is an Argonaute 2 (Ago2) ligand that acts by targeting the MicroRNA Binding Domain. | [Uses]
BCI-137 is a competitive AGO2 inhibitor, with an IC50 of 342 μM. BCI-137 tightly binds to several residues of the Mid domain[1]. | [References]
[1] Poser E, et, al. Surface Plasmon Resonance: A Useful Strategy for the Identification of Small Molecule Argonaute 2 Protein Binders. Methods Mol Biol. 2017;1517:223-237. DOI:10.1007/978-1-4939-6563-2_16 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|